Skip to main content
PMC home page
Gut logoLink to Gut
. 1981 Oct;22(10):845–848. doi: 10.1136/gut.22.10.845

Circulating immune complexes in patients with fulminant hepatic failure.

J Canalese, R J Wyke, D Vergani, A L Eddleston, R Williams
PMCID: PMC1419432  PMID: 7297915

Abstract

Circulating immune complexes were found in 15 of 16 patients with fulminant hepatic failure due to viral hepatitis and all of six patients who had had halothane anaesthesia; however, they were found in only five of 32 patients with paracetamol-induced hepatic necrosis. The levels of circulating immune complexes were not related to the severity of the clinical course, development of renal failure, final outcome, or severity of hypocomplementaemia. All the patients had depressed reticuloendothelial function as assessed by the clearance of 125I microaggregated albumin. These findings show that circulating immune complexes in fulminant hepatic failure are not simply a reflection of an immune response to liver antigens released as a result of the hepatic necrosis; nor are they a reflection of the failure of the reticuloendothelial system. This supports the view that circulating immune complexes are associated with immune mediated liver injury and may contribute to the process.

Full text

PDF
847

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Almeida J. D., Waterson A. P. The morphology of virus-antibody interaction. Adv Virus Res. 1969;15:307–338. doi: 10.1016/S0065-3527(08)60878-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Combes B., Shorey J., Barrera A., Stastny P., Eigenbrodt E. H., Hull A. R., Carter N. W. Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane. Lancet. 1971 Jul 31;2(7718):234–237. doi: 10.1016/s0140-6736(71)92572-4. [DOI] [PubMed] [Google Scholar]
  3. Czop J., Nussenzweig V. Studies on the mechanism of solubilization of immune precipitates by serum. J Exp Med. 1976 Mar 1;143(3):615–630. doi: 10.1084/jem.143.3.615. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Drivas G., Uldall P. R., Wardle N. Reticuloendothelial function in renal allograft recipients. Br Med J. 1975 Sep 27;3(5986):743–745. doi: 10.1136/bmj.3.5986.743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gimson A. E., Langley P. G., Hughes R. D., Canalese J., Mellon P. J., Williams R., Woods H. F., Weston M. J. Prostacyclin to prevent platelet activation during charcoal haemoperfusion in fulminant hepatic failure. Lancet. 1980 Jan 26;1(8161):173–175. doi: 10.1016/s0140-6736(80)90661-3. [DOI] [PubMed] [Google Scholar]
  6. Grün M., Liehr H., Rasenack U. Significance of endotoxaemia in experimental "galactosamine-hepatitis" in the rat. Acta Hepatogastroenterol (Stuttg) 1977 Apr;24(2):64–81. [PubMed] [Google Scholar]
  7. IIO M., WAGNER H. N., Jr, SCHEFFEL U., JABBOUR B. Studies of the reticuloendothelial system (RES). I. Measurement of the phagocytic capacity of the RES in man and dog. J Clin Invest. 1963 Mar;42:417–426. doi: 10.1172/JCI104729. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Martin A., Lachmann P. J., Halbwachs L., Hobart M. J. Haemolytic diffusion plate assays for factors B and D of the alternative pathway of complement activation. Immunochemistry. 1976 Apr;13(4):317–324. doi: 10.1016/0019-2791(76)90341-4. [DOI] [PubMed] [Google Scholar]
  9. Trepo C. G., Robert D., Motin J., Trepo D., Sepetjian M., Prince A. M. Hepatitis B antigen (HBSAg) and/or antibodies (anti-HBS and anti-HBC) in fulminant hepatitis: pathogenic and prognostic significance. Gut. 1976 Jan;17(1):10–13. doi: 10.1136/gut.17.1.10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Trey C., Davidson C. S. The management of fulminant hepatic failure. Prog Liver Dis. 1970;3:282–298. [PubMed] [Google Scholar]
  11. Vergani D., Mieli-Vergani G., Alberti A., Neuberger J., Eddleston A. L., Davis M., Williams R. Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N Engl J Med. 1980 Jul 10;303(2):66–71. doi: 10.1056/NEJM198007103030202. [DOI] [PubMed] [Google Scholar]
  12. Wilkinson S. P., Arroyo V., Gazzard B. G., Moodie H., Williams R. Relation of renal impairment and haemorrhagic diathesis to endotoxaemia in fulminant hepatic failure. Lancet. 1974 Mar 30;1(7857):521–524. doi: 10.1016/s0140-6736(74)92711-1. [DOI] [PubMed] [Google Scholar]
  13. Wilkinson S. P., Blendis L. M., Williams R. Frequency and type of renal and electrolyte disorders in fulminant hepatic failure. Br Med J. 1974 Feb 2;1(5900):186–189. doi: 10.1136/bmj.1.5900.186. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Woolf I. L., El Sheikh N., Cullens H., Lee W. M., Eddleston A. L., Williams R., Zuckerman A. J. Enhanced HBsAb production in pathogenesis of fulminant viral hepatitis type B. Br Med J. 1976 Sep 18;2(6037):669–671. doi: 10.1136/bmj.2.6037.669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Zubler R. H., Lange G., Lambert P. H., Miescher P. A. Detection of immune complexes in unheated sera by modified 125I-Clq binding test. Effect of heating on the binding of Clq by immune complexes and application of the test to systemic lupus erythematosus. J Immunol. 1976 Jan;116(1):232–235. [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES